Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations

被引：100
作者：
Ahn, Inhye E. [1 ]
Tian, Xin [1 ]
Wiestner, Adrian [1 ]
机构：
[1] NHLBI, Bldg 10, Bethesda, MD 20892 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 05期
关键词：
CLL;
D O I：
10.1056/NEJMc2005943
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with chronic lymphocytic leukemia with chromosome 17 abnormalities have a worse prognosis than those without such alterations. In this phase 2 study, patients who received continuous ibrutinib had a durable response that continued after 6.5 years in some patients.
引用
收藏
页码：498 / 500
页数：3
相关论文
共 5 条
  • [1] Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
    Ahn, Inhye E.
    Farooqui, Mohammed Z. H.
    Tian, Xin
    Valdez, Janet
    Sun, Clare
    Soto, Susan
    Lotter, Jennifer
    Housel, Stephanie
    Stetler-Stevenson, Maryalice
    Yuan, Constance M.
    Maric, Irina
    Calvo, Katherine R.
    Nierman, Pia
    Hughes, Thomas E.
    Saba, Nakhle S.
    Marti, Gerald E.
    Pittaluga, Stefania
    Herman, Sarah E. M.
    Niemann, Carsten U.
    Pedersen, Lone B.
    Geisler, Christian H.
    Childs, Richard
    Aue, Georg
    Wiestner, Adrian
    [J]. BLOOD, 2018, 131 (21) : 2357 - 2366
  • [2] Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
    Fischer, K.
    Al-Sawaf, O.
    Bahlo, J.
    Fink, A. -M.
    Tandon, M.
    Dixon, M.
    Robrecht, S.
    Warburton, S.
    Humphrey, K.
    Samoylova, O.
    Liberati, A. M.
    Pinilla-Ibarz, J.
    Opat, S.
    Sivcheva, L.
    Du, K. Le
    Fogliatto, L. M.
    Niemann, C. U.
    Weinkove, R.
    Robinson, S.
    Kipps, T. J.
    Boettcher, S.
    Tausch, E.
    Humerickhouse, R.
    Eichhorst, B.
    Wendtner, C. -M.
    Langerak, A. W.
    Kreuzer, K. -A.
    Ritgen, M.
    Goede, V.
    Stilgenbauer, S.
    Mobasher, M.
    Hallek, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (23) : 2225 - 2236
  • [3] Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
    O'Brien, Susan
    Jones, Jeffrey A.
    Coutre, Steven E.
    Mato, Anthony R.
    Hillmen, Peter
    Tam, Constantine
    Osterborg, Anders
    Siddiqi, Tanya
    Thirman, Michael J.
    Furman, Richard R.
    Ilhan, Osman
    Keating, Michael J.
    Call, Timothy G.
    Brown, Jennifer R.
    Stevens-Brogan, Michelle
    Li, Yunfeng
    Clow, Fong
    James, Danelle F.
    Chu, Alvina D.
    Hallek, Michael
    Stilgenbauer, Stephan
    [J]. LANCET ONCOLOGY, 2016, 17 (10) : 1409 - 1418
  • [4] Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
    Shanafelt, T. D.
    Wang, X. V.
    Kay, N. E.
    Hanson, C. A.
    O'Brien, S.
    Barrientos, J.
    Jelinek, D. F.
    Braggio, E.
    Leis, J. F.
    Zhang, C. C.
    Coutre, S. E.
    Barr, P. M.
    Cashen, A. F.
    Mato, A. R.
    Singh, A. K.
    Mullane, M. P.
    Little, R. F.
    Erba, H.
    Stone, R. M.
    Litzow, M.
    Tallman, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (05) : 432 - 443
  • [5] Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
    Woyach, J. A.
    Ruppert, A. S.
    Heerema, N. A.
    Zhao, W.
    Booth, A. M.
    Ding, W.
    Bartlett, N. L.
    Brander, D. M.
    Barr, P. M.
    Rogers, K. A.
    Parikh, S. A.
    Coutre, S.
    Hurria, A.
    Brown, J. R.
    Lozanski, G.
    Blachly, J. S.
    Ozer, H. G.
    Major-Elechi, B.
    Fruth, B.
    Nattam, S.
    Larson, R. A.
    Erba, H.
    Litzow, M.
    Owen, C.
    Kuzma, C.
    Abramson, J. S.
    Little, R. F.
    Smith, S. E.
    Stone, R. M.
    Mandrekar, S. J.
    Byrd, J. C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26) : 2517 - 2528
1